Small Cap Watch: AuMEGA, Lightning Minerals and Noxopharm advance key programs

Impact · against what's priced in

The updates provide positive catalysts for AuMEGA, Noxopharm, and Lightning Minerals by advancing early-stage exploration and regulatory timelines. These results move AAM beyond broad anomalies and establish a clearer clinical pathway for NOX, while L1M awaits confirmatory data for a new molybdenum target.

AAM+0.60

No priced-in read yet